Immuno-Oncology Conference 2018

SMi Group26 - 27 September, London, UK.
Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.

Agenda - Over 15 engaging presentations, case studies, keynote addresses, including:

  • Targeting immune checkpoints with Humabody VH therapeutics
  • Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy
  • Tumour mutation burden and the potential of its use as an indication of treatment choice
  • Unwanted immunogenicity and functionality testing of immuno-oncology drugs
  • New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology

Speakers - Over 15 leading experts in Immuno-Oncology field, including:

  • James Legg, Vice President R&D, Crescendo Biologics
  • Andrew Exley, Medical Assessor, MHRA
  • Harry Smith, Medical Scientist, Gilead Sciences
  • Grace Macaulay, Global Safety Physician Patient Safety Oncology, MedImmune
  • David Giljohan, CEO, Exicure
  • KandeepanGaneshalingam, Executive Director, Oncology Therapeutic Area Head, European Clinical Development, MSD
  • RochanaWickramasinghe, Director of Oncology Evaluation, AstraZeneca

Workshops - Carefully selected topics for further on-sight training. 2 pre-conference workshops (25 September) to provide in-depth knowledge on specific topics:

  • Strategic Competitive Intelligence in the Immuno-Oncology space - hosted by LucidQuest Ventures
  • Could the Microbiome boost Cancer Immuno-Therapy - hosted by ImmuneBiotech and Lund University

Networking - it is at the forefront of SMi events. 5+ hours of pure networking guaranteed. Follow event updates to be in the know about who will be joining the conversation.

For further details, please visit:
http://www.immuno-oncology-conference.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Novartis presents first-of-its-kind algorithm-base…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool a...

Trastuzumab deruxtecan demonstrated clinically-mea…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab ...

Genetic therapy heals damage caused by heart attac…

Researchers from King's College London have found that therapy that can induce heart cells to regenerate after a heart attack. Myocardial infarction, more commonly known ...